<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05003882</url>
  </required_header>
  <id_info>
    <org_study_id>Radicle</org_study_id>
    <secondary_id>RADX-2021-002</secondary_id>
    <nct_id>NCT05003882</nct_id>
  </id_info>
  <brief_title>Radicle ACES: A Study of Commercially Available CBD Used in the Real-world Setting</brief_title>
  <acronym>RWE-ACES</acronym>
  <official_title>A Randomized, Open-label Study of Commercially Available, Orally Ingestible, Cannabidiol (CBD) Products Used in the Real-world Setting for Pain, Sleep, and Anxiety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radicle Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radicle Science</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label study of commercially available, orally ingestible, Cannabidiol&#xD;
      (CBD) products used in the real-world setting for pain, sleep, and anxiety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radicle ACES is a real-world evidence study that aims to determine the effect of CBD on&#xD;
      overall well-being, anxiety, sleep, and pain over a 28-day period in treatment groups&#xD;
      compared to a waitlist control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Greater increase in overall well-being from baseline</measure>
    <time_frame>4 weeks</time_frame>
    <description>Overall well-being as assessed by KEMP Quality of Life Scale (QOL scale 1-7 where 7 is a better QOL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in overall well-being from baseline</measure>
    <time_frame>4 weeks</time_frame>
    <description>Overall well-being as assessed by World Health Organization (WHO) 5 Well Being Index (0-5 where 5 is better well-being)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in overall well-being from baseline</measure>
    <time_frame>4 weeks</time_frame>
    <description>Overall well-being as assessed by Patient Global Impression of Change (PGIC statement selection much improved to much worse)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in sleep from baseline</measure>
    <time_frame>4 weeks</time_frame>
    <description>Sleep as assessed by PROMIS (Patient Reported Outcome Measurement Information System) Sleep Short Form 8B (scale 1-5 where a 5 represents worse sleep)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sleep from baseline</measure>
    <time_frame>4 weeks</time_frame>
    <description>Sleep as assessed by PGIC (statement selection much improved to much worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety from baseline</measure>
    <time_frame>4 weeks</time_frame>
    <description>Anxiety as assessed by PGIC (statement selection much improved to much worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Less anxiety from baseline</measure>
    <time_frame>4 weeks</time_frame>
    <description>Anxiety as assessed by GAD-7 (scale 0-3 where 3 is greater anxiety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in anxiety from baseline</measure>
    <time_frame>4 weeks</time_frame>
    <description>Anxiety as assessed by PROMIS Anxiety 4A (scale 1-5 where 5 is greater anxiety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Less pain relative to baseline</measure>
    <time_frame>4 weeks</time_frame>
    <description>Pain as assessed by PEG (scale 1-10 where a higher score is greater pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain from baseline</measure>
    <time_frame>4 weeks</time_frame>
    <description>Pain as assessed by PGIC (statement selection much improved to much worse)</description>
  </secondary_outcome>
  <number_of_groups>14</number_of_groups>
  <enrollment type="Actual">3000</enrollment>
  <condition>Pain</condition>
  <condition>Sleep Disturbance</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <description>Commercially available, orally ingestible CBD product A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <description>Commercially available, orally ingestible CBD product B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <description>Commercially available, orally ingestible CBD product C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <description>Commercially available, orally ingestible CBD product D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E</arm_group_label>
    <description>Commercially available, orally ingestible CBD product E</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F</arm_group_label>
    <description>Commercially available, orally ingestible CBD product F</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm G</arm_group_label>
    <description>Commercially available, orally ingestible CBD product G</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm H</arm_group_label>
    <description>Commercially available, orally ingestible CBD product H</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <description>Commercially available, orally ingestible CBD product I</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm J</arm_group_label>
    <description>Commercially available, orally ingestible CBD product J</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm K</arm_group_label>
    <description>Commercially available, orally ingestible CBD product K</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm L</arm_group_label>
    <description>Commercially available, orally ingestible CBD product L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm M</arm_group_label>
    <description>Commercially available, orally ingestible CBD product M</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Waitlist control</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Commercially available, orally ingestible CBD product</intervention_name>
    <description>botanically-derived CBD extract product</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_label>Arm F</arm_group_label>
    <arm_group_label>Arm G</arm_group_label>
    <arm_group_label>Arm H</arm_group_label>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm J</arm_group_label>
    <arm_group_label>Arm K</arm_group_label>
    <arm_group_label>Arm L</arm_group_label>
    <arm_group_label>Arm M</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults (21 yo and older) living in the USA&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be 21 years of age&#xD;
&#xD;
          -  Live in the USA&#xD;
&#xD;
          -  Endorse symptoms of anxiety, chronic pain, or sleep disturbances as a primary reason&#xD;
             for taking a CBD product&#xD;
&#xD;
          -  Must have regular access to a computer, mobile device, and/or the internet to complete&#xD;
             surveys&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A person pregnant, trying to become pregnant or breastfeeding&#xD;
&#xD;
          -  Anyone diagnosed with liver disease or considered a heavy drinker&#xD;
&#xD;
          -  Anyone taking medication that warns against grapefruit consumption&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelsey Laird, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radicle Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radicle Science</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyssomnias</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>only aggregated and anonymized data will be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

